Sindbis virus (SINV) is a mosquito-borne Alphavirus responsible for outbreaks of SINV disease, mainly in north Europe. SINV has been isolated from mosquitoes in Israel since the 1980s but SINV disease outbreaks have never been recorded. Phylogenetic analysis showed all sequenced Israeli SINV strains belong to genotype I and form, together with SINV sequences from Saudi Arabia, a distinct Middle Eastern cluster. With high endemicity of SINV and as a major crossroads for bird migration between Africa and Eurasia, Israel provides valuable information on SINV dynamics and pathogenicity.
Furthermore, several SINV strains were isolated from a bird (Streptopelia turtur) in 1964 [19] and Cx. perexiguus and Cx. pipiens mosquitoes in 1967 and 1985 [14, 20] , suggesting that SINV was circulating in Israel. Interestingly, our records since the testing began in 2004 indicate that SINV infection in humans has rarely been diagnosed in Israel (our unpublished results), suggesting either that (1) SINV circulation in Israel is low; (2) SINV circulation in Israel is high in birds and/or mosquitoes but with little spillover to humans; (3) there is low clinical alert for SINV infections; or (4) SINV infection is asymptomatic in Israel. Therefore, it is a critical priority to characterize the current extent of circulation of SINV in mosquitoes and examine the genetic diversity of SINV in Israel.
Using the Israel national mosquito surveillance system, initially implemented toward identifying West Nile virus (WNV) circulation [21] , as a source, we tested the presence of SINV RNA in mosquito pools obtained during 2004-2006 and 2013-2015 and analyzed its genetic characteristics. Our findings demonstrate the high burden of SINV in mosquitoes in Israel and highlight the need to investigate the reason for the discrepancy between SINV mosquito circulation and human clinical infection. operated without light. It was not always possible to collect mosquitoes repeatedly from the same localities. However, a standard pattern of collection was established in 2001 and since then mosquitoes were routinely and periodically collected from selected areas across the country.
Specimen Processing
The catch was brought directly to the Laboratory of Entomology, Israel Ministry of Health. Species were identified according to morphological features [22] on laboratory chill tables (1431; BioQuip Rancho, Dominguez, CA) under a dissecting microscope. Only live mosquitoes were grouped in pools according to location, species, and sex (only female mosquitoes were subjected to further analysis). Once sorted, they were stored at −80°C until testing for SINV was initiated. The majority of pools comprised 50 specimens. Smaller pools were also examined when catches and/or survival of mosquitoes were low. For further processing and SINV detection, mosquito pools were transported on dry ice to the Israel National Center for Zoonotic Viruses, Central Virology Laboratories (CVL). At the CVL, each pool was homogenized in a Spex-CentriPrep (Meutuchen, NJ) mixer mill, followed by total RNA semiautomatic extraction using KingFisher (Thermo Electron Corporation, Waltham, MA), and MagMAX Viral RNA Isolation kit (Ambion, Austin, TX) according to manufacturer instructions.
Molecular and Sequence Analysis
RNA extracted from mosquito pools was tested for the presence of SINV RNA by TaqMan quantitative reverse transcription polymerase chain reaction (qRT-PCR) using specific primer probe sets for SINV nonstructural protein 1 (nsP1) as described [23] , using a Real-Time ABI Prism 7500 system (Applied Biosystems, Foster City, CA). The amplification of 768 nucleotides (nt) sequence containing the E2 envelope glycoprotein of SINV was performed using forward primer Sind16F and reverse primer Sind16R. Construction of 2116 nt sequence amplicons containing the capsid, E2, E3, 6 kDa, and E1 proteins of SINV was generated using forward primers Sind15F, Sind16F, Sind17F, and reverse primers Sind15R, Sind16R, Sind17R [24] . Both strands of the amplicons were sequenced on an ABI 3500 Genetic Analyzer (Applied Biosystems) using an ABI PRISM BigDye Terminator Cycle Sequencing Kit (Applied Biosystems) and the corresponding SINV primers.
Geographic Distribution of Sampling Locations
The 671 location sites, which had GPS coordinates and were reported during 2004-2006 and 2013-2015 , were displayed on a map constructed using Arc GIS ArcMap 10.3.
Phylogenetic Analysis
Phylogenetic trees were inferred using the maximum likelihood method implemented in jModelTest v2.1.10 [25] and Bayesian Markov chain Monte Carlo (MCMC) approach available in BEAST v1.8 [26] . Analyses were performed under the best fit nucleotide substitution model identified as the general time reversible model plus invariant sites-distributed rate heterogeneity (GTR+I) by all model selection methods run in jModelTest2. The relaxed molecular clock model was chosen, with the uncorrelated lognormal distribution using an approximate continuous time Markov chain rate reference prior for the mean and an exponential with mean 1/3 for the standard deviation. A uniform prior on (0, 1) was used for the nucleotide frequencies. The MCMC was run for 10 million iterations, with a 10% burn-in period and samples saved every 10 000 iterations. The tree was visualized using FigTree v1.4.3.
RESULTS

During 2004-2006 and 2013-2015
, 111 730 mosquitoes were tested in 3008 pools for SINV RNA using qRT-PCR. The total number of mosquitoes and mosquito pools that were analyzed in each year, including the number and percentage of SINV RNA positive pools, and the minimum infection rate (MIR), which is calculated as the ratio of the number of positive pools to the total number of mosquitoes tested and represents the number of infected mosquitoes per 1000 tested, are presented in Table 1 . Altogether, a total of 191 pools (6.35%) were positive for SINV RNA, demonstrating the high circulation of SINV in Israel. Interestingly, except for 2006 which had substantially higher MIR and percentage of positive pools, all other years showed similar infection rates ( Table 1 ), suggesting that SINV is endemic in Israel. Abbreviation: MIR, minimum infection rate.
Next, we examined which of the mosquito species circulating in Israel were infected with SINV. Our results ( In order to characterize the geographic distribution of collection sites and SINV-infected mosquitoes, we generated spa- Based on the Ct values of SINV RNA detected by qRT-PCR (Ct values below 30), RNA derived from 50 SINV positive pools representing isolates from all years surveyed in addition to 1 SINV strain, which was isolated in 1983 from mosquitoes in Israel (Sindbis PELEG) [14, 27] , and 5 SINV strains isolated from mosquitoes in 2002, was selected for sequencing and subsequent time scale phylogenetic analysis. The phylogenetic tree, based on 641 nt of the E2 gene (Figure 2 ), demonstrates that all the Israeli strains belong to 1 cluster within SINV genotype I and are in close relationship with SINV strains that were isolated from Cx. univitattus mosquitoes in Saudi Arabia in 1980.
Sindbis (Figure 2 ), all Israeli strains cluster with the Saudi Arabia isolates (Supplementary Figure 1) . The South African and 1 of the China strains did not cluster with the Northern European strains; however, these results were not significant (posterior probability < 0.9). According to the phylogenetic analysis, the Middle Eastern cluster separated sometime between 1930 and 1950 and shows a 8% nucleic acid differences from the other genotype I strains, while the difference between SINV genotypes I and II is 25%.
DISCUSSION
Several studies have shown that birds are the main amplifying hosts of SINV and that the virus is able to infect many bird species in Europe, the Middle East, Africa, Asia, Australia, and New Zealand [16, 28] . The identity and dynamics of SINV strains circulating in Israel is specifically interesting in light of the fact that an important route of bird migration from Africa to Euroasia passes through Israel. In this study, we found that SINV is highly endemic in Israel and that the spatial distribution of SINV in mosquitoes has possibly been modified over the years. Furthermore, our results indicate that all of the Israeli strains sequenced belong to SINV genotype I-the same genotype that is responsible for Sindbis fever outbreaks in South Africa and several countries in Northern Europe.
Viruses are separated into families based on their genetic and protein organization. SINV belongs to the genus Alphavirus in the virus family Togaviridae, which includes also Chikungunya viruse. WNV belongs to the Flaviviridae family, which includes also the dengue and Zika viruses. Despite the taxonomic distance, SINV and WNV share several similarities-both circulate in mosquitoes and birds, only incidentally infect humans, and their primary vectors are members of the Culex mosquitoes. In fact, when comparing the SINV (this study) and WNV [21] positive mosquito pools, we observed that 23% (45 mosquito pools) of all mosquito pools tested were positive for both SINV and WNV, suggesting that these 2 viruses are not only co-circulating in the same geographic locations but also in the same mosquito pools, and perhaps also in the same mosquito. Furthermore, the kinetics of both viruses seems to be similar in some years; such was the case in 2006 in which the MIR and percentage of positive pools were distinctively high for both SINV (Table 1) and WNV [21] . Because WNV is responsible for approximately 80 hospitalized human cases in Israel annually, it is important to examine SINV infection in humans in Israel and its spatial distribution. The total number (191 pools) and percentage (6.35%) of SINV-positive mosquito pools (Table 1) found in this study indicate a high circulation rate of the virus in mosquitoes in Israel. As far as we know, this is the first all-country annual systemic surveillance of SINV described and very few other SINVendemic countries have examined the circulation of SINV in mosquitoes: SINV mosquito surveillance conducted during the summer of 2009 in Germany and Sweden found 1.5% and 17% (infection rate of 36 infections/1000 mosquitoes) SINV-positive mosquito pools, respectively [24, 29] ; however, the surveillance included only 643 pools captured from 3 sites in Southwest Germany [24] and 81 pools from Central Sweden [29] . In Finland, 1 SINV strain was isolated from approximately 80 mosquito pools collected during 2005-2009 using only tissue culture virus isolation without qRT-PCR [15] . Finally, in the Witwatersrand-Pretoria region in South Africa, infection rates for the mosquito vector Cx. univittatus collected during a SINV outbreak in 1983-1984, were 5.4/1000 mosquitoes [3] . Because mosquitoes are the primary source for SINV infection, implementation of a national mosquito surveillance system in SINVendemic countries is important in order to introduce efficient and preventive measures for reducing the risk of SINV infection in humans, as performed for WNV in WNV-endemic countries.
One of the primary aims of our study is to determine which SINV genotypes have been circulating in Israel in the past years. Our phylogenetic analysis demonstrated that all Israeli sequences belong to a single cluster within SINV genotype I. Several SINV strains isolated in Israel in different years clustered together while other Israeli strains isolated in the same year were phylogenically further apart, suggesting that, similar to WNV circulation in Israel [21] and SINV circulation in Finland [15] , endemic circulation of SINV in nonmigratory birds and seasonal transmission enhanced by migratory birds both exist in Israel.
The phylogenetic differences observed in this study between the Middle Eastern cluster, consisting of all Israeli and Saudi Arabian strains, and the other SINV genotype I isolates from Finland, Sweden, Russia, South Africa, and Germany are of special interest. Based on our timeline phylogenetic tree (Figure 2) , it is plausible that SINV was introduced from Israel into Saudi Arabia sometime before 1983; however, earlier Middle Eastern strains are needed to examine the spread of SINV into the Middle East. These results, shown by the 641nt tree, were validated using longer viral sequences from a few representative strains, demonstrating the robustness of the Middle Eastern cluster. Several more SINV strains reported from South European and Middle Eastern countries have a limited sequence available (approximately 300 bp) [17] and therefore we could not use them in this study. Because outbreaks of SINV infections in humans associated with symptomatic disease have been reported only from areas of Northern Europe and South Africa, it is tempting to speculate that strains belonging to the Middle Eastern cluster might be less pathogenic or less infective to humans than strains constituting the other cluster within genotype I. Indeed, Sindbis disease was first observed in South Africa in 1963 [30] , in Sweden in 1967, and in Finland in 1974 [1] , fitting with the timeline of the Nordic/South African strain divergence before this in about 1930 (Figure 2 ). However, 2 findings that challenge this hypothesis are the detection of SINV strains similar to North European strains in 1964 in a Streptopelia turtur bird in Israel [19] and in several mosquito pools in Southwest Germany [24] , areas where no SINV symptomatic disease outbreaks have been reported. Future studies should assess the seroprevalence of SINV in Israel and investigate the differences in virulence between the North European and Middle Eastern SINV strains.
In conclusion, while SINV is highly endemic in Israel and its circulation may possibly be expanding geographically over the years, all SINV strains sequenced in this study are very similar and form a distinct Middle Eastern cluster within SINV genotype I. As a major crossroads for bird migration, surveillance for SINV in mosquitoes in Israel can provide valuable information for SINV circulation and dynamics in Africa and Eurasia.
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